|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract |
| Jeffrey Frankel, MD |
| Patient perception of meaningful reductions in bothersome symptoms of overactive bladder (OAB) is lacking. In the phase 3 EMPOWUR trial, vibegron significantly reduced the average daily number of micturitions, urgency episodes, and urge urinary incontinence (UUI) episodes vs placebo. This analysis assessed the meaningfulness of reductions in clinical endpoints observed in EMPOWUR using the patient's perception of improvement. |
|
|
|
|
|
|
|
|
|
|
|
| The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder |
| Michael A. Weber, MD |
| Diane Newman is joined by Michael Weber discussing a novel medication, Vibegron, for the treatment of overactive bladder and a study Dr. Weber presented at the AUA 2021 Annual Meeting. |
|
|
|
|
|
|
|
|
|
|
|
| Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder
|
| Anne Agur, Ph.D.
|
| Diane Newman is joined by Anne Agur to share how they collect data to develop novel models of the human saphenous nerve. These novel models of the human saphenous nerve will be used to develop neuromodulation therapy approaches, both an engineering finite element approach, and for clinicians to look at electrode placement.
|
|
|
|
|
|
|
|
|
|
|
|
| Trends in Overactive Bladder Therapy Utilization: An Evaluation of the Impact of Clinical Care Pathways and Practice Guidelines |
| Claire Burton, Amy Zhang, Alayne Markland, and Ekene Enemchukwu |
| Evidence-based treatments are available for overactive bladder (OAB) with published guidelines and treatment pathways created for clinicians to optimize treatment and provide a clinical framework for diagnosis and treatment. The impact of these efforts remains unclear and medical treatment pathways are poorly understood. This study evaluated overall trends in therapy utilization before and after the 2014 AUA/SUFU OAB guideline amendment and publication of the OAB clinical care pathway in 2016. |
|
|
|
|
|
| Vibegron Statistically Significantly Improves Quality-of-Life Measures in Patients with Overactive Bladder: EMPOWUR Study |
| Jeffrey Frankel, MD |
| EMPOWUR evaluated the efficacy and safety of vibegron, a new β3-agonist, vs placebo with tolterodine (active control) in adults with overactive bladder (OAB). Vibegron had statistically significant adjusted mean reductions from baseline (P<0.001) in daily micturition and urge urinary incontinence (UUI) episodes vs placebo from Week 2 through Week 12. Patient-reported quality of life (QOL) data are presented here. |
|
|
|
|
|
| Overactive Bladder (OAB) and Urinary Incontinence Clinical Care Pathway
|
| Diane K. Newman, DNP, ANP-BC, FAAN
|
| Overactive bladder (OAB) is a symptom complex of lower urinary tract symptoms of urgency, frequency with or without urinary incontinence. It is prevalent in both men and women (10.8% and 12.8% respectively). According to Irwin and colleagues (2006), women have a higher rate (13.1% vs 5.4%) of urinary incontinence (urgency, stress, or mixed), are more likely (19% vs 12%) to report frequency of more than eight times per day, and are more bothered by urinary frequency than men (66% vs 46%).
|
|
|
|
|
|
| A 3D Digital Map of the Human Saphenous Nerve: A Neuroanatomical Approach to Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder |
| Michael Peng, Paul Yoo, and Anne Agur |
| Saphenous nerve (SAFN) stimulation is an emerging treatment for overactive bladder (OAB) syndrome, but precise knowledge of the subcutaneous distribution of nerve branches is lacking. This study volumetrically documented and modeled in 3D the course of branches of the SAFN relative to bony/soft tissue landmarks. |
|
|
|
|
|
|
|
|
|
|
